SCHEMBL4014782

SCHEMBL4014782

CC(C)(C)C1=CC[CH]C(c2cccc(Cl)c2)=C1

nearest known ligand 0.36

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.36
HTR2C P28335 2/20 0.35
ESR2 Q92731 1/20 0.34
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
ALOX5 P09917 1/20 0.33
TAAR1 Q96RJ0 2/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CNR2 P34972 1/20 0.32
IDO1 P14902 1/20 0.32
HTR1A P08908 1/20 0.32
HTR7 P34969 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6047625 0.85 HTR2C (0.35) HTR2CESR2ALDH1A1ALOX5TAAR1
SCHEMBL4811614 0.80 AHR (0.39) PGR
SCHEMBL4801089 0.77 NOTUM (0.40) HTR2CTAAR1
SCHEMBL9650518 0.76 HTR2C (0.37) HTR2CESR2ALDH1A1CYP1A2ALOX5
SCHEMBL4808925 0.76 GSTP1 (0.35) ESR2ALDH1A1CYP1A2ALOX5
SCHEMBL6407852 0.74 CACNA2D1 (0.38) HTR2CALDH1A1CYP1A2TAAR1
SCHEMBL5887075 0.74 PTGS2 (0.39) PGRHTR2CESR2HTR1AHTR7
SCHEMBL4155393 0.73 KIF11 (0.45) ALDH1A1CYP1A2
SCHEMBL6047597 0.70 AR (0.38) ALDH1A1CHRNB4CHRNA3
SCHEMBL6047587 0.68 HTR2C (0.42) HTR2CIDO1HTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US claimed
EP-1781617-A4 ALPHA, BETA-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION JANSSEN PHARMACEUTICA NV (BE) 2009-06-24 EP disclosed
US-7465808-B2 CCK-1 receptor modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2008-12-16 US disclosed
EP-1781617-A2 ALPHA, BETA-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-09 EP disclosed
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20060014817-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2006-01-19 US disclosed
WO-2006004742-A2 α, β-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION JANSSEN PHARAMCEUTICA N.V. (BE) 2006-01-12 WO disclosed
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration JANSSEN PHARMACEUTICA N.V. (BE) 2006-01-05 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R PGR 244/4885HTR2C 41/4885ESR2 720/4885
US-20060014817-A1 CCK-1 receptor modulators CCKAR, CCKBR, GIPR PGR 280/4885HTR2C 255/4885ESR2 336/4885
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration CCKAR, CCKBR, FFAR1 PGR 212/4885HTR2C 403/4885ESR2 122/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R PGR 153/4885HTR2C 123/4885ESR2 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.